Phase II Evaluation of Anguidine (NSC 141537) in 5-Day Courses in Colorectal Adenocarcinoma A Southeastern Cancer Study Group Trial

Publisher Website
Google Scholar
Abstract
Thirty-three patients with advanced colorectal adenocarcinoma were treated with daily Anguidine i.v. 5 mg/m2 × 5 for 3 weeks. The patients were stratified into two groups: prior chemotherapy and no prior chemotherapy. No responses were noted. Major toxicities were hypotension and fever.